サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1678714

不眠症治療の市場規模、シェア、動向分析レポート：タイプ別、販売チャネル別、地域別、セグメント予測、2025年～2030年

Insomnia Therapeutics Market Size, Share & Trends Analysis Report By Type (Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonists, Melatonin Antagonists), By Sales Channel, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
不眠症治療の市場規模、シェア、動向分析レポート：タイプ別、販売チャネル別、地域別、セグメント予測、2025年～2030年
出版日: 2025年02月12日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

不眠症治療市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の不眠症治療市場規模は2030年までに37億4,000万米ドルに達し、2025～2030年のCAGRは4.5％を記録すると予測されています。

同市場は主に、特許取得済み分子の存在、潜在的な臨床パイプライン候補、ストレスレベルの上昇、入眠が困難な高齢者の増加によって牽引されています。不眠症の有病率の増加、この疾患に対する認識、より安全な薬剤の入手可能性などが、収益の伸びを促進すると予想されます。

不眠症は世界人口の約35％が罹患していると推定されています。不眠症のさまざまなパターンには、入眠障害と睡眠維持障害があり、一般に頻繁な覚醒と早すぎる覚醒を伴い、再び眠ることが困難です。長期にわたる不眠症は日常生活に支障をきたし、その結果、非生産的な労働時間となることもあります。この状態を放置すると、重度のうつ病や神経衰弱につながる可能性があります。

不眠症治療市場の成長に影響を与える要因には、ストレスレベルの上昇、市場における特許分子の存在、臨床パイプラインにある潜在的な薬剤、技術的に先進的医療機器の導入、高齢者の増加などがあります。睡眠不足が日常生活に与える影響に対する意識の高まりは、不眠症に対する様々な治療法の採用率を高めると予想され、不眠症治療市場の収益成長につながると期待されています。

現在、不眠症の治療として広く採用されているのは、オレキシン拮抗薬やメラトニン拮抗薬などの新規薬剤が市場に出回っているジェネリックの非ベンゾジアゼピン系薬剤や抗うつ薬などです。エーザイのレンボレキサントの発売は、このセグメントにおけるアンメット・メディカル・ニーズに応え、予測期間中の市場の成長を促進すると期待されます。2015年の国連報告書によると、60歳以上の人口は56%増加し、2030年には約14億人に達すると予測されています。これらの統計は、高齢者が増加していることを示しています。このような人口層は睡眠不足に陥りやすいため、不眠症治療の需要が増加すると予測されています。

不眠症治療市場のレポートハイライト

  • ベンゾジアゼピン系薬剤が市場を独占し、2024年のシェアは29.1%。ベンゾジアゼピン系薬剤は、急性ストレスに伴う不眠症に有用です。抗うつ薬は予測期間中に大きな成長が見込まれます。
  • 市販薬（OTC）が市場をリードし、2024年には61.6％のシェアを占めました。処方薬治療は、人々の間で薬剤やその消費に関する意識が高まっていることを背景に、予測期間中に急成長すると予測されています。
  • 北米の不眠症治療市場は、2024年の収益シェア35.4％で世界市場を独占しています。同地域の市場成長は、不眠症の罹患率の上昇、意識レベルの向上、同地域の高い医療支出によるものです。
  • アジア太平洋の不眠症治療市場は、予測期間中に最速のCAGR 5.3%を記録すると予想されます。アジア太平洋の不眠症治療市場は、不眠症治療市場で大きな成長が見込まれています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 不眠症治療市場の変数、動向、範囲

  • 市場系統の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 産業分析-ポーターのファイブフォース分析
    • PESTLE分析

第4章 不眠症治療市場：タイプビジネス分析

  • タイプの市場シェア、2024年と2030年
  • タイプセグメントダッシュボード
  • 市場規模と予測と動向分析、タイプ別、2018～2030年
  • ベンゾジアゼピン
  • 非ベンゾジアゼピン
  • 抗うつ薬
  • オレキシン拮抗薬
  • メラトニン拮抗薬
  • その他

第5章 不眠症治療市場：販売チャネルビジネス分析

  • 販売チャネルの市場シェア、2024年と2030年
  • 販売チャネルセグメントダッシュボード
  • 市場規模と予測と動向分析、販売チャネル別、2018～2030年
  • 処方薬
  • 市販薬（OTC）

第6章 不眠症治療市場：地域別、推定・動向分析

  • 地域別市場シェア分析、2024年と2030年
  • 地域別市場ダッシュボード
  • 市場規模、予測動向分析、2018～2030年
  • 北米
    • 国別、2018～2030年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 国別、2018～2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • デンマーク
    • スウェーデン
  • アジア太平洋
    • 国別、2018～2030年
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • 国別、2018～2030年
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 国別、2018～2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • Takeda Pharmaceutical Company Limited
    • VANDA PHARMACEUTICALS
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Mylan NV（Viatris Inc.）
    • Sumitomo Pharma Co., Ltd.
    • Sanofi
    • Paratek Pharmaceuticals, Inc.
    • Ebb Therapeutics（Kryo）
図表

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global insomnia therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 5. Global insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 6. North America insomnia therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 7. North America insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 8. North America insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 9. U.S. insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 10. U.S. Insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 11. Canada insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 12. Canada insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 13. Mexico insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 14. Mexico insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 15. Europe insomnia therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 16. Europe insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 17. Europe insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 18. UK insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 19. UK Insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 20. Germany insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 21. Germany insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 22. France insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 23. France Insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 24. Italy insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 25. Italy insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 26. Spain insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 27. Spain insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 28. Norway insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 29. Norway Insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 30. Denmark insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 31. Denmark insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 32. Sweden insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 33. Sweden insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 34. Asia Pacific insomnia therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 35. Asia Pacific insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 36. Asia Pacific insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 37. Japan insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 38. Japan insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 39. China insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 40. China insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 41. India insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 42. India insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 43. Australia insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 44. Australia insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 45. South Korea insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 46. South Korea insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 47. Thailand insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 48. Thailand insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 49. Latin America insomnia therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 50. Latin America insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 51. Latin America insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 52. Brazil insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 53. Brazil insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 54. Argentina insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 55. Argentina insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 56. Middle East & Africa Insomnia therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 57. Middle East & Africa insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 58. Middle East & Africa insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 59. South Africa insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 60. South Africa insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 61. Saudi Arabia insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 62. Saudi Arabia insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 63. UAE insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 64. UAE insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 65. Kuwait insomnia therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 66. Kuwait insomnia therapeutics market, by sales channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Insomnia therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Type and sales channel outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Insomnia therapeutics market dynamics
  • Fig. 12 Insomnia therapeutics market: Porter's five forces analysis
  • Fig. 13 Insomnia therapeutics market: PESTLE analysis
  • Fig. 14 Insomnia therapeutics market: Type segment dashboard
  • Fig. 15 Insomnia therapeutics market: Type market share analysis, 2024 & 2030
  • Fig. 16 Benzodiazepines market, 2018 - 2030 (USD Million)
  • Fig. 17 Nonbenzodiazepines market, 2018 - 2030 (USD Million)
  • Fig. 18 Antidepressants market, 2018 - 2030 (USD Million)
  • Fig. 19 Orexin antagonists market, 2018 - 2030 (USD Million)
  • Fig. 20 Melatonin antagonists market, 2018 - 2030 (USD Million)
  • Fig. 21 Others market, 2018 - 2030 (USD Million)
  • Fig. 22 Insomnia therapeutics market: Sales channel segment dashboard
  • Fig. 23 Insomnia therapeutics market: Sales channel market share analysis, 2024 & 2030
  • Fig. 24 Prescription market, 2018 - 2030 (USD Million)
  • Fig. 25 Over-the-counter (OTC) market, 2018 - 2030 (USD Million)
  • Fig. 26 Insomnia therapeutics market revenue, by region
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 Regional marketplace: Key takeaways
  • Fig. 29 North America insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. country dynamics
  • Fig. 31 U.S. insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 32 Canada country dynamics
  • Fig. 33 Canada insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 34 Mexico country dynamics
  • Fig. 35 Mexico insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 36 Europe insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 37 UK country dynamics
  • Fig. 38 UK insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 39 Germany country dynamics
  • Fig. 40 Germany insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 41 France country dynamics
  • Fig. 42 France insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 43 Italy country dynamics
  • Fig. 44 Italy insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 45 Spain country dynamics
  • Fig. 46 Spain insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 47 Norway country dynamics
  • Fig. 48 Norway insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 49 Sweden country dynamics
  • Fig. 50 Sweden insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 51 Denmark country dynamics
  • Fig. 52 Denmark insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 53 Asia Pacific insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 54 Japan country dynamics
  • Fig. 55 Japan insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 56 China country dynamics
  • Fig. 57 China insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 58 India country dynamics
  • Fig. 59 India insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 60 Australia country dynamics
  • Fig. 61 Australia insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 62 South Korea country dynamics
  • Fig. 63 South Korea insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 64 Thailand country dynamics
  • Fig. 65 Thailand insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 66 Latin America insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 67 Brazil country dynamics
  • Fig. 68 Brazil insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 69 Argentina country dynamics
  • Fig. 70 Argentina insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 71 MEA insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 72 South Africa country dynamics
  • Fig. 73 South Africa insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 74 Saudi Arabia country dynamics
  • Fig. 75 Saudi Arabia insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 76 UAE country dynamics
  • Fig. 77 UAE insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 78 Kuwait country dynamics
  • Fig. 79 Kuwait insomnia therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 80 Company categorization
  • Fig. 81 Company market position analysis
  • Fig. 82 Strategic framework
目次
Product Code: GVR-2-68038-213-6

Insomnia Therapeutics Market Growth & Trends:

The global insomnia therapeutics market size is expected to reach USD 3.74 billion by 2030, registering a CAGR of 4.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the presence of patented molecules, potential clinical pipeline candidates, rising stress level, and increase in geriatric population who find it difficult to fall asleep. Increase in prevalence of insomnia & awareness about this condition and availability of safer drugs are anticipated to fuel revenue growth.

Insomnia is estimated to affect approximately 35% of the global population. Different patterns of the condition include difficulty in sleep initiation and maintenance, which is generally accompanied with frequent awakenings & awakening too early with trouble sleeping again. Long-term insomnia can hamper everyday life, which may result in nonproductive work hours. If left untreated, this condition may lead to severe depression and nervous breakdown of the patient.

Factors influencing insomnia therapeutics market growth include rising stress level, presence of patented molecules in the market, potential drugs in clinical pipeline, introduction of technologically advanced medical devices, and growing geriatric population. Growing awareness about the impact of sleep deprivation on everyday life is anticipated to increase adoption rate of various treatments for insomnia, which is expected to lead to revenue growth of the insomnia therapeutics market.

Currently, widely adopted treatment options for insomnia include generic nonbenzodiazepines and antidepressants even though other novel agents such as orexin antagonists and melatonin antagonists are available in the market. Launch of Eisai's Lemborexant is expected to cater to unmet medical needs in this segment and fuel growth of this market over the forecast period. According to United Nations (UN) report in 2015, population in the age group of 60 years and above is projected to grow by 56% and is expected to reach around 1.4 billion by 2030. These statistics indicate the growing geriatric population. Since this population base is more susceptible to sleep deprivation, the demand for insomnia therapeutics is anticipated to increase.

Insomnia Therapeutics Market Report Highlights:

  • Benzodiazepines dominated the market and accounted for a share of 29.1% in 2024. Benzodiazepines are useful for insomnia associated with acute stress. Antidepressants are expected to grow lucratively over the forecast period.
  • Over-the-counter (OTC) led the market and accounted for a share of 61.6% in 2024, owing to the increasing number of patients with insomnia. Prescription therapeutics are projected to grow rapidly over the forecast period, fueled by the increasing awareness regarding drugs and their consumption amongst people.
  • North America insomnia therapeutics market dominated the global market with a revenue share of 35.4% in 2024. Market growth in the region is due to the rising incidence of insomnia disorders, the increase in awareness levels, and high healthcare spending in this region.
  • Asia Pacific insomnia therapeutics market is expected to register the fastest CAGR of 5.3% in the forecast period. Asia Pacific insomnia therapeutics market is anticipated to witness significant growth in the insomnia therapeutics market.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Sales Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Insomnia Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Insomnia Therapeutics Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Benzodiazepines
    • 4.4.1. Benzodiazepines Market, 2018 - 2030 (USD Million)
  • 4.5. Nonbenzodiazepines
    • 4.5.1. Nonbenzodiazepines Market, 2018 - 2030 (USD Million)
  • 4.6. Antidepressants
    • 4.6.1. Antidepressants Market, 2018 - 2030 (USD Million)
  • 4.7. Orexin Antagonists
    • 4.7.1. Orexin Antagonists Market, 2018 - 2030 (USD Million)
  • 4.8. Melatonin Antagonists
    • 4.8.1. Melatonin Antagonists Market, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Insomnia Therapeutics Market: Sales Channel Business Analysis

  • 5.1. Sales Channel Market Share, 2024 & 2030
  • 5.2. Sales Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2018 to 2030 (USD Million)
  • 5.4. Prescription
    • 5.4.1. Prescription Market, 2018 - 2030 (USD Million)
  • 5.5. Over-the-Counter (OTC)
    • 5.5.1. Over-the-Counter (OTC) Market, 2018 - 2030 (USD Million)

Chapter 6. Insomnia Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Insomnia Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Insomnia Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Insomnia Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Insomnia Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Insomnia Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Insomnia Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Insomnia Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Insomnia Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Insomnia Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Insomnia Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Norway
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Norway Insomnia Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Denmark
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Denmark Insomnia Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Sweden
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Insomnia Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Insomnia Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Insomnia Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Insomnia Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Insomnia Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Insomnia Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Insomnia Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Insomnia Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Insomnia Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Insomnia Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Insomnia Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Insomnia Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Insomnia Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Insomnia Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Insomnia Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Insomnia Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Takeda Pharmaceutical Company Limited
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. VANDA PHARMACEUTICALS
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Merck & Co., Inc.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Pfizer Inc.
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Teva Pharmaceutical Industries Ltd.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Mylan N.V. (Viatris Inc.)
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Sumitomo Pharma Co., Ltd.
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Sanofi
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Paratek Pharmaceuticals, Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Ebb Therapeutics (Kryo)
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives